Tatva Chintan Pharma Chem Limited — Investor Meet, 09-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Tatva Chintan reported Q4 revenue of ₹108 Cr, up 10% YoY and 26% QoQ, while EBITDA fell 43% YoY to ₹9 Cr with margins at 8.3%, impacted by operational inefficiencies from multiple new agro intermediates ramp-up. FY25 revenue was ₹383 Cr with EBITDA of ₹34 Cr at 8.9% margins. Management expects FY26 revenue growth above 25%, driven by SDA and PASC demand recovery and 200%+ growth in electrolyte salts. New agro intermediate supplies begin Q3 FY26, with a ₹105-110 Cr plant operational by Jan ’26. EBITDA margins are forecast to improve to ~20% as efficiencies stabilize. Early recovery in SDA and progress in ultra-pure semiconductor chemicals highlight ongoing innovation and capacity expansion. Management remains cautiously optimistic on a phased growth path.